Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01158157 | VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV | PHASE3 | COMPLETED | 25 | — | — | Sep 13, 2010 | Feb 14, 2012 | Mar 18, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Vaccination | OTHER | This study was a single arm study. All eligible subjects received ACAM2000. |
| Name | Type | Description |
|---|---|---|
| ACAM2000 | BIOLOGICAL | Percutaneous administration of a droplet (2.5µg) of ACAM2000 using a bifurcated needle. |
Inclusion Criteria: * Signed written informed consent. * Age 18 - 65 years. * Normal and healthy as determined by medical history, physical exam, vital signs and clinical laboratory tests at screening visit. * Subject must meet all required subject suitability criteria that pertain to normal Source...